A cost-minimisation analysis of lobectomy: thoracoscopic versus posterolateral thoracotomy

William R. Burfeind, Nikhil P. Jaik, Nestor Villamizar, Eric M. Toloza, David H. Harpole, Thomas A. D'Amico

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Objective: Recent evidence suggests that lobectomy performed either through thoracoscopy (TL) or via a posterolateral thoracotomy (PLT) produces equivalent oncologic outcomes in appropriately selected patients. Advantages of thoracoscopic lobectomy include decreased postoperative pain, shorter length of stay, fewer postoperative complications and better compliance with adjuvant chemotherapy. This study evaluates the costs associated with lobectomy performed thoracoscopically or via thoracotomy. Methods: This is a retrospective analysis of actual costing and prospectively collected health-related quality of life (QOL) outcomes. Between 2002 and 2004, 113 patients underwent lobectomy (PLT: n = 37; TL: n = 76) and completed QOL assessments both preoperatively and 1-year postoperatively. Actual fixed and variable direct costs from the preoperative, hospitalisation and 30-day postoperative phases were captured using a T1 cost accounting system and were combined with actual professional collections. Cost-utility analysis was performed by transforming a global QOL measurement to an estimate of utility and calculating a quality-adjusted life year (QALY) for each patient. Results: Baseline characteristics were similar in the two groups. Total costs ($US) were significantly greater for the strategy of PLT ($12,119) than for TL ($10,084; p = 0.0012). Even when only stage I and II lung cancers were included (n = 32 PLT, n = 69 TL), total costs for PLT were still higher than that for TL ($11,998 vs $10,120; p = 0.005). The mean QALY for the PLT group was 0.74 ± 0.22 and for the TL group was 0.72 ± 0.18 (p = 0.68). Conclusions: In this retrospective analysis, TL was significantly less expensive than PLT from the preoperative evaluation through 30 days postoperatively, with overall savings of approximately $2000 per patient. In light of equivalent QALY outcomes, this cost-utility analysis supports increased adoption of TL as a cost-minimisation strategy. The use of TL for the 50,000 lobectomies performed in the United States each year would represent a savings of approximately $100 million.

Original languageEnglish (US)
Pages (from-to)827-832
Number of pages6
JournalEuropean Journal of Cardio-thoracic Surgery
Volume37
Issue number4
DOIs
StatePublished - Apr 2010
Externally publishedYes

Fingerprint

Thoracotomy
Costs and Cost Analysis
Quality-Adjusted Life Years
Quality of Life
Cost-Benefit Analysis
Thoracoscopy
Adjuvant Chemotherapy
Postoperative Pain
Length of Stay
Lung Neoplasms
Hospitalization

Keywords

  • Cost
  • Lobectomy
  • Lung cancer
  • Thoracoscopy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery
  • Pulmonary and Respiratory Medicine

Cite this

A cost-minimisation analysis of lobectomy : thoracoscopic versus posterolateral thoracotomy. / Burfeind, William R.; Jaik, Nikhil P.; Villamizar, Nestor; Toloza, Eric M.; Harpole, David H.; D'Amico, Thomas A.

In: European Journal of Cardio-thoracic Surgery, Vol. 37, No. 4, 04.2010, p. 827-832.

Research output: Contribution to journalArticle

Burfeind, William R. ; Jaik, Nikhil P. ; Villamizar, Nestor ; Toloza, Eric M. ; Harpole, David H. ; D'Amico, Thomas A. / A cost-minimisation analysis of lobectomy : thoracoscopic versus posterolateral thoracotomy. In: European Journal of Cardio-thoracic Surgery. 2010 ; Vol. 37, No. 4. pp. 827-832.
@article{295833139324400b8780f5138cf3c8e0,
title = "A cost-minimisation analysis of lobectomy: thoracoscopic versus posterolateral thoracotomy",
abstract = "Objective: Recent evidence suggests that lobectomy performed either through thoracoscopy (TL) or via a posterolateral thoracotomy (PLT) produces equivalent oncologic outcomes in appropriately selected patients. Advantages of thoracoscopic lobectomy include decreased postoperative pain, shorter length of stay, fewer postoperative complications and better compliance with adjuvant chemotherapy. This study evaluates the costs associated with lobectomy performed thoracoscopically or via thoracotomy. Methods: This is a retrospective analysis of actual costing and prospectively collected health-related quality of life (QOL) outcomes. Between 2002 and 2004, 113 patients underwent lobectomy (PLT: n = 37; TL: n = 76) and completed QOL assessments both preoperatively and 1-year postoperatively. Actual fixed and variable direct costs from the preoperative, hospitalisation and 30-day postoperative phases were captured using a T1 cost accounting system and were combined with actual professional collections. Cost-utility analysis was performed by transforming a global QOL measurement to an estimate of utility and calculating a quality-adjusted life year (QALY) for each patient. Results: Baseline characteristics were similar in the two groups. Total costs ($US) were significantly greater for the strategy of PLT ($12,119) than for TL ($10,084; p = 0.0012). Even when only stage I and II lung cancers were included (n = 32 PLT, n = 69 TL), total costs for PLT were still higher than that for TL ($11,998 vs $10,120; p = 0.005). The mean QALY for the PLT group was 0.74 ± 0.22 and for the TL group was 0.72 ± 0.18 (p = 0.68). Conclusions: In this retrospective analysis, TL was significantly less expensive than PLT from the preoperative evaluation through 30 days postoperatively, with overall savings of approximately $2000 per patient. In light of equivalent QALY outcomes, this cost-utility analysis supports increased adoption of TL as a cost-minimisation strategy. The use of TL for the 50,000 lobectomies performed in the United States each year would represent a savings of approximately $100 million.",
keywords = "Cost, Lobectomy, Lung cancer, Thoracoscopy",
author = "Burfeind, {William R.} and Jaik, {Nikhil P.} and Nestor Villamizar and Toloza, {Eric M.} and Harpole, {David H.} and D'Amico, {Thomas A.}",
year = "2010",
month = "4",
doi = "10.1016/j.ejcts.2009.10.017",
language = "English (US)",
volume = "37",
pages = "827--832",
journal = "European Journal of Cardio-thoracic Surgery",
issn = "1010-7940",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - A cost-minimisation analysis of lobectomy

T2 - thoracoscopic versus posterolateral thoracotomy

AU - Burfeind, William R.

AU - Jaik, Nikhil P.

AU - Villamizar, Nestor

AU - Toloza, Eric M.

AU - Harpole, David H.

AU - D'Amico, Thomas A.

PY - 2010/4

Y1 - 2010/4

N2 - Objective: Recent evidence suggests that lobectomy performed either through thoracoscopy (TL) or via a posterolateral thoracotomy (PLT) produces equivalent oncologic outcomes in appropriately selected patients. Advantages of thoracoscopic lobectomy include decreased postoperative pain, shorter length of stay, fewer postoperative complications and better compliance with adjuvant chemotherapy. This study evaluates the costs associated with lobectomy performed thoracoscopically or via thoracotomy. Methods: This is a retrospective analysis of actual costing and prospectively collected health-related quality of life (QOL) outcomes. Between 2002 and 2004, 113 patients underwent lobectomy (PLT: n = 37; TL: n = 76) and completed QOL assessments both preoperatively and 1-year postoperatively. Actual fixed and variable direct costs from the preoperative, hospitalisation and 30-day postoperative phases were captured using a T1 cost accounting system and were combined with actual professional collections. Cost-utility analysis was performed by transforming a global QOL measurement to an estimate of utility and calculating a quality-adjusted life year (QALY) for each patient. Results: Baseline characteristics were similar in the two groups. Total costs ($US) were significantly greater for the strategy of PLT ($12,119) than for TL ($10,084; p = 0.0012). Even when only stage I and II lung cancers were included (n = 32 PLT, n = 69 TL), total costs for PLT were still higher than that for TL ($11,998 vs $10,120; p = 0.005). The mean QALY for the PLT group was 0.74 ± 0.22 and for the TL group was 0.72 ± 0.18 (p = 0.68). Conclusions: In this retrospective analysis, TL was significantly less expensive than PLT from the preoperative evaluation through 30 days postoperatively, with overall savings of approximately $2000 per patient. In light of equivalent QALY outcomes, this cost-utility analysis supports increased adoption of TL as a cost-minimisation strategy. The use of TL for the 50,000 lobectomies performed in the United States each year would represent a savings of approximately $100 million.

AB - Objective: Recent evidence suggests that lobectomy performed either through thoracoscopy (TL) or via a posterolateral thoracotomy (PLT) produces equivalent oncologic outcomes in appropriately selected patients. Advantages of thoracoscopic lobectomy include decreased postoperative pain, shorter length of stay, fewer postoperative complications and better compliance with adjuvant chemotherapy. This study evaluates the costs associated with lobectomy performed thoracoscopically or via thoracotomy. Methods: This is a retrospective analysis of actual costing and prospectively collected health-related quality of life (QOL) outcomes. Between 2002 and 2004, 113 patients underwent lobectomy (PLT: n = 37; TL: n = 76) and completed QOL assessments both preoperatively and 1-year postoperatively. Actual fixed and variable direct costs from the preoperative, hospitalisation and 30-day postoperative phases were captured using a T1 cost accounting system and were combined with actual professional collections. Cost-utility analysis was performed by transforming a global QOL measurement to an estimate of utility and calculating a quality-adjusted life year (QALY) for each patient. Results: Baseline characteristics were similar in the two groups. Total costs ($US) were significantly greater for the strategy of PLT ($12,119) than for TL ($10,084; p = 0.0012). Even when only stage I and II lung cancers were included (n = 32 PLT, n = 69 TL), total costs for PLT were still higher than that for TL ($11,998 vs $10,120; p = 0.005). The mean QALY for the PLT group was 0.74 ± 0.22 and for the TL group was 0.72 ± 0.18 (p = 0.68). Conclusions: In this retrospective analysis, TL was significantly less expensive than PLT from the preoperative evaluation through 30 days postoperatively, with overall savings of approximately $2000 per patient. In light of equivalent QALY outcomes, this cost-utility analysis supports increased adoption of TL as a cost-minimisation strategy. The use of TL for the 50,000 lobectomies performed in the United States each year would represent a savings of approximately $100 million.

KW - Cost

KW - Lobectomy

KW - Lung cancer

KW - Thoracoscopy

UR - http://www.scopus.com/inward/record.url?scp=77949490876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949490876&partnerID=8YFLogxK

U2 - 10.1016/j.ejcts.2009.10.017

DO - 10.1016/j.ejcts.2009.10.017

M3 - Article

C2 - 19939695

AN - SCOPUS:77949490876

VL - 37

SP - 827

EP - 832

JO - European Journal of Cardio-thoracic Surgery

JF - European Journal of Cardio-thoracic Surgery

SN - 1010-7940

IS - 4

ER -